CEMIのチャート
CEMIの企業情報
| symbol | CEMI |
|---|---|
| 会社名 | Chembio Diagnostics Inc （ケムバイオ・ダイアグノスティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Chembio Diagnostics Inc. (Chembio) and its subsidiary Chembio Diagnostic Systems Inc. develop manufacture market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples and are manufactured in a standard cassette format a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies. ケムバイオ・ダイアグノスティクスは、米国の検査製品メ―カ―。感染症を検出するポイントオブケアの診断テストを開発、製造、販売、またライセンス供与を行う。主な製品には、ヒト免疫不全ウイルス（HIV）抗体検出テスト（カセット形式、ディップスティック形式、バレル形式）、梅毒検出テスト、イヌのリ―シュマニア症検出テストなどがある。 |
| 本社所在地 | 3661 Horseblock Road Medford NY 11763 USA |
| 代表者氏名 | John J. Sperzel ジョン・J.・スペルゼル |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 631-924-1135 |
| 設立年月日 | 31382 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 165人 |
| url | www.chembio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cemi |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -4.13082 |
| 終値（lastsale） | 9.7 |
| 時価総額（marketcap） | 137484114 |
| 時価総額 | 時価総額（百万ドル） 136.77540 |
| 売上高 | 売上高（百万ドル） 30.01290 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 127.69617 |
| 当期純利益 | 当期純利益（百万ドル） -4.96381 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Chembio Diagnostics Inc revenues increased 57% to $16.4M. Net loss decreased 37% to $2.4M. Revenues reflect North America segment increase from $1.8M to $6M Africa segment increase from $863K to $3.9M. Lower net loss reflects Stock-based Compensation in R&D decrease of 72% to $16K (expense) Interest Income increase of 44% to $30K (income). |
CEMIのテクニカル分析
CEMIのニュース
Royce & Associates reduced stake in Chembio Diagnostics Inc 2021/01/29 16:00:26 Investing.com
https://www.investing.com/news/stock-market-news/royce--associates-reduced-stake-in-chembio-diagnostics-inc-2403592
Chembio Diagnostics Reports Third Quarter 2020 Financial Results 2020/11/05 21:05:00 GlobeNewswire
HAUPPAUGE, N.Y., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on…
Return On Capital Employed Overview: Chembio Diagnostics 2020/10/02 10:10:00 Benzinga
During Q2, Chembio Diagnostics's (NASDAQ: CEMI) reported sales totaled $5.11 million. Despite a 66.92% in earnings, the company posted a loss of $7.27 …
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Chembio Diagnostics, Inc. (CEMI) 2020/08/14 16:00:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $CEMI #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 17, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ: CEMI) common stock between April 1, 2020 and June 16, 2020, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. In April 2020, the Company’s COVID-19 antibody test w
Chembio Diagnostics EPS misses by $0.02, beats on revenue (NASDAQ:CEMI) 2020/08/06 20:53:33 Seeking Alpha
Chembio Diagnostics (NASDAQ:CEMI): Q2 GAAP EPS of -$0.42 misses by $0.02. Revenue of $5.11M (-46.7% Y/Y) beats by $0.5M. Shares -1.7%. Press Release
Chembio Diagnostics Reports Third Quarter 2020 Financial Results 2020/11/05 21:05:00 GlobeNewswire
HAUPPAUGE, N.Y., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on…
Return On Capital Employed Overview: Chembio Diagnostics 2020/10/02 10:10:00 Benzinga
During Q2, Chembio Diagnostics's (NASDAQ: CEMI) reported sales totaled $5.11 million. Despite a 66.92% in earnings, the company posted a loss of $7.27 …
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Chembio Diagnostics, Inc. (CEMI) 2020/08/14 16:00:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $CEMI #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 17, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ: CEMI) common stock between April 1, 2020 and June 16, 2020, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. In April 2020, the Company’s COVID-19 antibody test w
Chembio Diagnostics EPS misses by $0.02, beats on revenue (NASDAQ:CEMI) 2020/08/06 20:53:33 Seeking Alpha
Chembio Diagnostics (NASDAQ:CEMI): Q2 GAAP EPS of -$0.42 misses by $0.02. Revenue of $5.11M (-46.7% Y/Y) beats by $0.5M. Shares -1.7%. Press Release
Shareholder Alert: Robbins LLP Reminds Investors Chembio Diagnostics, Inc. (CEMI) Sued for Misleading Shareholders 2020/07/16 18:32:00 Business Wire
SAN DIEGO & SALT LAKE CITY--(BUSINESS WIRE)---- $CEMI #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Chembio Diagnostics, Inc. (NASDAQ: CEMI) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between March 12, 2020 and June 16, 2020. Chembio develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. If you suffered a loss as a result of Chembio'
Chembio Diagnostics Reports Third Quarter 2020 Financial Results 2020/11/05 21:05:00 GlobeNewswire
HAUPPAUGE, N.Y., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on…
Return On Capital Employed Overview: Chembio Diagnostics 2020/10/02 10:10:00 Benzinga
During Q2, Chembio Diagnostics's (NASDAQ: CEMI) reported sales totaled $5.11 million. Despite a 66.92% in earnings, the company posted a loss of $7.27 …
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Chembio Diagnostics, Inc. (CEMI) 2020/08/14 16:00:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $CEMI #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 17, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ: CEMI) common stock between April 1, 2020 and June 16, 2020, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. In April 2020, the Company’s COVID-19 antibody test w
Chembio Diagnostics EPS misses by $0.02, beats on revenue (NASDAQ:CEMI) 2020/08/06 20:53:33 Seeking Alpha
Chembio Diagnostics (NASDAQ:CEMI): Q2 GAAP EPS of -$0.42 misses by $0.02. Revenue of $5.11M (-46.7% Y/Y) beats by $0.5M. Shares -1.7%. Press Release
Shareholder Alert: Robbins LLP Reminds Investors Chembio Diagnostics, Inc. (CEMI) Sued for Misleading Shareholders 2020/07/16 18:32:00 Business Wire
SAN DIEGO & SALT LAKE CITY--(BUSINESS WIRE)---- $CEMI #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Chembio Diagnostics, Inc. (NASDAQ: CEMI) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between March 12, 2020 and June 16, 2020. Chembio develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. If you suffered a loss as a result of Chembio'